As already mentioned, a possible explanation for such results is that non-enhancing gliomas represent an earlier form, where the role of IDH mutations for tumor growth is still crucial, while enhancing “transformed” IDH-mutated LGGs are driven by the acquisition of additional mutations, with limited susceptibility to therapeutic reversion of epigenetic changes induced by IDH-mut. Here, IDH2 is linked to neoplasm.